TW201206423A - Use of dronedarone for the preparation of a medicament for use in the prevention of cardiovascular hospitalization or of mortality in patients having a first recurrence of atrial fibrillation or atrial flutter - Google Patents

Use of dronedarone for the preparation of a medicament for use in the prevention of cardiovascular hospitalization or of mortality in patients having a first recurrence of atrial fibrillation or atrial flutter Download PDF

Info

Publication number
TW201206423A
TW201206423A TW100116576A TW100116576A TW201206423A TW 201206423 A TW201206423 A TW 201206423A TW 100116576 A TW100116576 A TW 100116576A TW 100116576 A TW100116576 A TW 100116576A TW 201206423 A TW201206423 A TW 201206423A
Authority
TW
Taiwan
Prior art keywords
atrial
atrial fibrillation
patients
flutter
dronedarone
Prior art date
Application number
TW100116576A
Other languages
English (en)
Chinese (zh)
Inventor
Christophe Gaudin
Eickels Martin Van
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of TW201206423A publication Critical patent/TW201206423A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
TW100116576A 2010-05-11 2011-05-11 Use of dronedarone for the preparation of a medicament for use in the prevention of cardiovascular hospitalization or of mortality in patients having a first recurrence of atrial fibrillation or atrial flutter TW201206423A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP10305504A EP2386300A1 (fr) 2010-05-11 2010-05-11 Utilisation de la dronédarone pour la préparation d'un médicament destiné à la prévention de l'hospitalisation cardiovasculaire ou de la mortalité chez des patients souffrant d'une première répétition de fibrillation auriculaire ou de flutter auriculaire

Publications (1)

Publication Number Publication Date
TW201206423A true TW201206423A (en) 2012-02-16

Family

ID=42732045

Family Applications (1)

Application Number Title Priority Date Filing Date
TW100116576A TW201206423A (en) 2010-05-11 2011-05-11 Use of dronedarone for the preparation of a medicament for use in the prevention of cardiovascular hospitalization or of mortality in patients having a first recurrence of atrial fibrillation or atrial flutter

Country Status (5)

Country Link
EP (1) EP2386300A1 (fr)
AR (1) AR081031A1 (fr)
TW (1) TW201206423A (fr)
UY (1) UY33381A (fr)
WO (1) WO2011141872A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3195862A1 (fr) 2008-04-17 2017-07-26 Sanofi Utilisation de la dronedarone dans la preparation d'un medicament utilise pour prevenir un episode cardiovasculaire menant a l'hospitalisation ou prevenir la fibrillation auriculaire
US8602215B2 (en) 2010-06-30 2013-12-10 Sanofi Methods for reducing the risk of an adverse dronedarone/beta-blockers interaction in a patient suffering from atrial fibrillation

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2665444B1 (fr) 1990-08-06 1992-11-27 Sanofi Sa Derives d'amino-benzofuranne, benzothiophene ou indole, leur procede de preparation ainsi que les compositions les contenant.
EP3195862A1 (fr) * 2008-04-17 2017-07-26 Sanofi Utilisation de la dronedarone dans la preparation d'un medicament utilise pour prevenir un episode cardiovasculaire menant a l'hospitalisation ou prevenir la fibrillation auriculaire

Also Published As

Publication number Publication date
UY33381A (es) 2011-12-30
WO2011141872A1 (fr) 2011-11-17
AR081031A1 (es) 2012-05-30
EP2386300A1 (fr) 2011-11-16

Similar Documents

Publication Publication Date Title
TWI519298B (zh) 決奈達隆（ｄｒｏｎｅｄａｒｏｎｅ）於製備用於預防心血管疾病住院或死亡之藥劑之用途
US20110166220A1 (en) Dronedarone for the prevention of permanent atrial fibrillation
AU2009278864A1 (en) Use of dronedarone for the preparation of a medicament for the prevention of stroke or transient ischemic attack
TW200946108A (en) Use of dronedarone or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for regulating the potassium level in the blood
US20110166221A1 (en) Use of dronedarone for the preparation of a medicament for use in the prevention of cardioversion
TW201206423A (en) Use of dronedarone for the preparation of a medicament for use in the prevention of cardiovascular hospitalization or of mortality in patients having a first recurrence of atrial fibrillation or atrial flutter
TW200951117A (en) Combination of dronedarone with at least one diuretic, therapeutic application thereof
WO2012020377A1 (fr) Utilisation du dronédarone pour la préparation d'un médicament destiné à maîtriser le rythme et la fréquence chez des patients atteints de fibrillation auriculaire
TW201208676A (en) Use of dronedarone for the preparation of a medicament for the prevention of cardiovascular hospitalization or of mortality in patients with lone atrial fibrillation
EP2387997A1 (fr) Utilisation de la dronédarone pour la préparation d'un médicament pour la prévention d'événements cardiovasculaires chez des patients souffrant de fibrillation auriculaire permanente tout au long de la période d'administration de la dronédarone
TW201529068A (zh) 決奈達隆（ｄｒｏｎｅｄａｒｏｎｅ）於製備用於預防心血管疾病住院或死亡之藥劑之用途
TW201200131A (en) Use of dronedarone for the preparation of a medicament for the prevention of cardiovacular hospitalizations or death or cardiovascular events in patients with premanent atrial fibrillation
EP2387996A1 (fr) Utilisation de la dronédarone pour la préparation d'un médicament destiné à la prévention d'événements cardiovasculaires chez des patients souffrant de fibrillation auriculaire permanente
WO2012013750A1 (fr) Utilisation de la dronédarone pour la préparation d'un médicament pour la réduction du taux d'hospitalisations d'un patient souffrant de fibrillation auriculaire